vs

Side-by-side financial comparison of MEDICINOVA INC (MNOV) and Singularity Future Technology Ltd. (SGLY). Click either name above to swap in a different company.

Singularity Future Technology Ltd. is the larger business by last-quarter revenue ($147.6K vs $123.3K, roughly 1.2× MEDICINOVA INC). Singularity Future Technology Ltd. runs the higher net margin — -451.2% vs -2473.6%, a 2022.3% gap on every dollar of revenue.

Medicinova Inc. is a clinical-stage biopharmaceutical firm developing novel therapies for unmet medical needs, focusing on immunology, inflammatory disorders and oncology. It operates across North America and Asia, advancing pipeline candidates through clinical trials to serve patients with limited treatment options.

Singularity Education Group is an American company that offers executive educational programs, a business incubator, and business consultancy services. Although the company uses the word "university" in its branding, it is not an accredited university and has no academic programs or accreditation.

MNOV vs SGLY — Head-to-Head

Bigger by revenue
SGLY
SGLY
1.2× larger
SGLY
$147.6K
$123.3K
MNOV
Higher net margin
SGLY
SGLY
2022.3% more per $
SGLY
-451.2%
-2473.6%
MNOV

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
MNOV
MNOV
SGLY
SGLY
Revenue
$123.3K
$147.6K
Net Profit
$-3.1M
$-665.9K
Gross Margin
Operating Margin
-2741.7%
-407.0%
Net Margin
-2473.6%
-451.2%
Revenue YoY
-68.9%
Net Profit YoY
-6.9%
-103.1%
EPS (diluted)
$-0.06
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MNOV
MNOV
SGLY
SGLY
Q4 25
$147.6K
Q3 25
$123.3K
$307.9K
Q2 25
$134.6K
$474.1K
Q1 25
$363.1K
Q4 24
$474.6K
Q3 24
$501.4K
Q2 24
$832.9K
Q1 24
$446.6K
Net Profit
MNOV
MNOV
SGLY
SGLY
Q4 25
$-665.9K
Q3 25
$-3.1M
$-9.5M
Q2 25
$-3.3M
$-952.5K
Q1 25
$-1.7M
Q4 24
$-327.8K
Q3 24
$-961.8K
Q2 24
$-918.8K
Q1 24
$-949.8K
Gross Margin
MNOV
MNOV
SGLY
SGLY
Q4 25
Q3 25
3.4%
Q2 25
2.1%
Q1 25
83.4%
Q4 24
2.2%
Q3 24
-54.2%
Q2 24
-10.6%
Q1 24
-59.9%
Operating Margin
MNOV
MNOV
SGLY
SGLY
Q4 25
-407.0%
Q3 25
-2741.7%
-183.5%
Q2 25
-2679.9%
38.0%
Q1 25
-325.5%
Q4 24
-144.2%
Q3 24
-204.5%
Q2 24
-115.4%
Q1 24
-313.2%
Net Margin
MNOV
MNOV
SGLY
SGLY
Q4 25
-451.2%
Q3 25
-2473.6%
-3077.1%
Q2 25
-2437.7%
-200.9%
Q1 25
-460.1%
Q4 24
-69.1%
Q3 24
-191.8%
Q2 24
-110.3%
Q1 24
-212.7%
EPS (diluted)
MNOV
MNOV
SGLY
SGLY
Q4 25
$-0.12
Q3 25
$-0.06
$-2.25
Q2 25
$-0.07
$-0.24
Q1 25
$-0.46
Q4 24
$-0.09
Q3 24
$-0.27
Q2 24
$-1.54
Q1 24
$-0.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MNOV
MNOV
SGLY
SGLY
Cash + ST InvestmentsLiquidity on hand
$32.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$44.0M
$4.7M
Total Assets
$47.6M
$21.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MNOV
MNOV
SGLY
SGLY
Q4 25
Q3 25
$32.6M
Q2 25
$34.3M
Q1 25
Q4 24
$15.2M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
MNOV
MNOV
SGLY
SGLY
Q4 25
$4.7M
Q3 25
$44.0M
$3.1M
Q2 25
$46.9M
$12.5M
Q1 25
$13.6M
Q4 24
$14.7M
Q3 24
$12.1M
Q2 24
$16.0M
Q1 24
$14.3M
Total Assets
MNOV
MNOV
SGLY
SGLY
Q4 25
$21.6M
Q3 25
$47.6M
$17.6M
Q2 25
$49.8M
$18.2M
Q1 25
$18.4M
Q4 24
$19.1M
Q3 24
Q2 24
$18.7M
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MNOV
MNOV
SGLY
SGLY
Operating Cash FlowLast quarter
$-1.7M
$-8.6M
Free Cash FlowOCF − Capex
$-1.7M
FCF MarginFCF / Revenue
-1383.5%
Capex IntensityCapex / Revenue
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MNOV
MNOV
SGLY
SGLY
Q4 25
$-8.6M
Q3 25
$-1.7M
$-1.3M
Q2 25
$-2.3M
$-2.3M
Q1 25
$-745.2K
Q4 24
$407.0K
Q3 24
$-9.1K
Q2 24
$126.0K
Q1 24
$1.4M
Free Cash Flow
MNOV
MNOV
SGLY
SGLY
Q4 25
Q3 25
$-1.7M
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
FCF Margin
MNOV
MNOV
SGLY
SGLY
Q4 25
Q3 25
-1383.5%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Capex Intensity
MNOV
MNOV
SGLY
SGLY
Q4 25
Q3 25
2.4%
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons